stoxline Quote Chart Rank Option Currency Glossary
  
Evaxion Biotech A/S (EVAX)
2.49  -0.12 (-4.6%)    02-14 16:00
Open: 2.61
High: 2.79
Volume: 1,500,126
  
Pre. Close: 2.61
Low: 2.4304
Market Cap: 1(M)
Technical analysis
2025-02-14 4:47:52 PM
Short term     
Mid term     
Targets 6-month :  8.06 1-year :  11.44
Resists First :  6.9 Second :  9.8
Pivot price 2.82
Supports First :  2.22 Second :  1.84
MAs MA(5) :  2.62 MA(20) :  3.15
MA(100) :  8.12 MA(250) :  13.24
MACD MACD :  -0.6 Signal :  -0.6
%K %D K(14,3) :  6.5 D(3) :  6.3
RSI RSI(14): 39.8
52-week High :  22.5 Low :  2.22
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ EVAX ] has closed above bottom band by 33.2%. Bollinger Bands are 45% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.8 - 2.81 2.81 - 2.83
Low: 2.39 - 2.41 2.41 - 2.43
Close: 2.46 - 2.49 2.49 - 2.52
Company Description

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Headline News

Sun, 16 Feb 2025
Evaxion Biotech A/S ADR (EVAX) Receives Upgrades Amid Sharp Decline – Is It Time for Investors to Reevaluate? - HPBL

Sun, 16 Feb 2025
Evaxion Biotech (EVAX) Stock Analysis: Price Decline, Analyst Ratings and Financial Ratios – market - HPBL

Fri, 14 Feb 2025
Evaxion secures Nasdaq listing with equity boost - MSN

Fri, 14 Feb 2025
Evaxion Biotech A/S Secures Nasdaq Compliance, Extends Cash Runway to Mid-2026 - Nasdaq

Fri, 14 Feb 2025
Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination -February 14, 2025 at 08:00 am EST - Marketscreener.com

Fri, 14 Feb 2025
Financial Turnaround: Evaxion Secures Future with $17M Raise, Dodges Delisting - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 6 (M)
Shares Float 36 (M)
Held by Insiders 9.2 (%)
Held by Institutions 10.2 (%)
Shares Short 102 (K)
Shares Short P.Month 24 (K)
Stock Financials
EPS -14
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -57.4 %
Return on Assets (ttm) -69.5 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0.52
Sales Per Share 0.52
EBITDA (p.s.) -2.38
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.18
PEG Ratio 0
Price to Book value 249
Price to Sales 4.74
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android